August 8, 2024 11:49 AM EDT
R&D

Lil­ly’s an­ti-tau pill for Alzheimer’s fails in Phase 2 study

Ryan Cross

Senior Science Correspondent

One month af­ter the long-await­ed ap­proval of its first Alzheimer’s drug, Eli Lil­ly said that an­oth­er ex­per­i­men­tal med­i­cine aimed at slow­ing de­men­tia …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

Ar­bor Biotech­nolo­gies cuts ear­ly-stage dis­cov­ery work, lays off staff

FDA ap­proves sub­cu­ta­neous Ocre­vus, broad­en­ing ac­cess to Roche and Genen­tech block­buster

Post-Hoc: Big promis­es built Mod­er­na. They might al­so be its un­do­ing

Af­ter a huge IPO and ac­qui­si­tion, Zymer­gen caps off bank­rupt­cy with $30M SEC penal­ty

Doug Williams re­turns with a ‘FIT’ bet on CAR-Ts; Bio­gen ap­points Mene Pan­ga­los to board

A service from the Financial Times